Advances in Therapy最新文献

{"title":"Increased Adiposity and Dyslipidemia in Young Men Living with HIV Compared to Matched PrEP Users: A Cross-Sectional Study.","authors":"Felice Cinque, Arianna Liparoti, Stefania Varchetta, Giorgio Bozzi, Valeria Castelli, Serena Ludovisi, Antonio Muscatello, Elena Trombetta, Marta Tornese, Bianca Mariani, Cristina Bertelli, Giuseppina Pisano, Erika Fatta, Annalisa Cespiati, Giovanna Oberti, Silvia Gentile, Anna Ludovica Fracanzani, Rosa Lombardi, Alessandra Bandera","doi":"10.1007/s12325-026-03540-4","DOIUrl":"https://doi.org/10.1007/s12325-026-03540-4","url":null,"abstract":"<p><strong>Introduction: </strong>This study compares anthropometric, metabolic, cardiovascular, and liver parameters in people living with HIV (PLWH) on antiretroviral therapy (ART), and men on pre-exposure prophylaxis (PrEP) in the same age group.</p><p><strong>Methods: </strong>This was a single-center, cross-sectional study of males aged 18-50 years, receiving ART for HIV or PrEP for at least 6 months, consecutively enrolled at Policlinico Hospital, Milan. Lifestyle factors were assessed using the International Physical Activity Questionnaire and a food diary. Anthropometric measurements included body mass index (BMI), waist circumference, and bioimpedance analysis. Blood samples were analyzed for glycemic parameters, lipid profile, hepatic enzymes, and adipokines, including leptin. Hepatic steatosis and fibrosis were evaluated using FibroScan^®. Group differences were assessed using chi-squared, t tests, and Mann-Whitney tests, while logistic regression determined associations with HIV status.</p><p><strong>Results: </strong>Eighty-two participants were enrolled: 53 PLWH and 29 PrEP users. PLWH had significantly higher BMI, waist circumference, total fat mass, and triglycerides, as well as total and LDL cholesterol. PrEP users engaged in more vigorous-intensity activity, with no differences in dietary habits. Among PLWH, higher physical activity was associated with lower HOMA index. Leptin levels were significantly higher in PLWH compared to PrEP users. Multivariate analysis identified LDL cholesterol as independently associated with HIV status.</p><p><strong>Conclusion: </strong>PLWH exhibited greater adiposity and dyslipidemia than PrEP users, with leptin emerging as a potential marker of metabolic dysfunction. Higher physical activity was linked to improved insulin sensitivity, underscoring the role of exercise in mitigating HIV-related metabolic dysregulation.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis.","authors":"Christopher T Ritchlin, Laura C Coates, Philip J Mease, Désirée van der Heijde, Proton Rahman","doi":"10.1007/s12325-026-03563-x","DOIUrl":"https://doi.org/10.1007/s12325-026-03563-x","url":null,"abstract":"<p><p>Psoriatic arthritis (PsA) is a chronic inflammatory disease with a heterogeneous presentation including peripheral joint arthritis, axial inflammation, enthesitis, dactylitis, and psoriatic skin and nail changes. A substantial proportion of patients develop structural joint damage that can be monitored using standard radiographs. In patients with PsA, structural damage progression has been associated with significant impairment of physical function, health-related quality of life, and work productivity. Tumor necrosis factor inhibitors were the first biologic therapies approved for patients with PsA and have demonstrated efficacy in reducing the rate of structural damage progression in these patients. More recently, biologics targeting the interleukin (IL)-23p19 subunit (guselkumab and risankizumab) and IL-17 (secukinumab, ixekizumab, and bimekizumab) have been approved to treat patients with active PsA and are the subject of this review, with a focus on guselkumab. In separate phase 3, randomized, controlled studies, participants with active PsA treated with guselkumab, secukinumab, ixekizumab, and bimekizumab exhibited less structural damage progression in comparison with placebo. Both guselkumab and risankizumab inhibit the IL-23p19 subunit; however, to date, only guselkumab has demonstrated statistically significant efficacy in inhibiting structural damage progression in this patient population.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF).","authors":"Seth H Walters, Stephane Soulard, Weicheng Ye, Aldo Elsen, Thitima Kongnakorn, Sayooj S Raj, Pratik Pimple, Pedro G Ferreira, Antoine Froidure","doi":"10.1007/s12325-026-03601-8","DOIUrl":"https://doi.org/10.1007/s12325-026-03601-8","url":null,"abstract":"<p><strong>Introduction: </strong>Early treatment for progressive pulmonary fibrosis (PPF) improves outcomes. However, diagnosis of fibrotic-interstitial lung diseases (fibrotic ILDs) and detection of potentially emergent PPF are delayed by 9-12 months on average. New ILD diagnostic and PPF monitoring strategies are being investigated to enable early treatment and improve patient outcomes.</p><p><strong>Methods: </strong>A time-to-event cost-effectiveness model for reducing delays in ILD diagnosis and PPF detection was developed. Model inputs were obtained from ILD expert clinicians, the literature, and statistical progression equations derived from the INBUILD trial. The study investigated discounted health economic outcomes of early diagnosis of ILD and detection of PPF in eight European countries (Belgium, Denmark, Finland, Greece, Norway, The Netherlands, Portugal, and Sweden).</p><p><strong>Results: </strong>The study highlights substantial benefits from reducing the time to diagnose fibrotic ILD and identifying PPF across various ILD subtypes. Clinical advantages arise from any reduction in diagnostic delays, primarily by delaying the onset of PPF and facilitating earlier nintedanib treatment. The model indicates that earlier diagnosis results in quality-adjusted life-year (QALY) gains across all countries, with improvements ranging from 0.061 to 0.084 in the base case. Furthermore, all tested scenarios confirm the cost-effectiveness of early diagnosis of fibrotic ILD and of PPF detection across all studied countries.</p><p><strong>Conclusion: </strong>Early diagnosis of ILD and detection of PPF yield cost-effective clinical benefits, supporting the adoption of approaches to speed up ILD diagnosis and PPF detection.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT02999178.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147831749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison.","authors":"John Anderson, Nihal Narsipur, Douglas Jones, Andrew Smith, Anurag Relan, Emily Aiello, Neil Roskell, Adam Gough, Sakshi Jindal, Ketsia Habimana, Hannah Kilvert, H Henry Li, Amanda Harrington","doi":"10.1007/s12325-026-03605-4","DOIUrl":"https://doi.org/10.1007/s12325-026-03605-4","url":null,"abstract":"<p><strong>Introduction: </strong>Prompt and effective on-demand treatment is critical in hereditary angioedema (HAE). Although multiple on-demand therapies are available, including recombinant human C1 esterase inhibitor (rhC1-INH) and sebetralstat, no head-to-head efficacy trials exist.</p><p><strong>Methods: </strong>A series of indirect treatment comparisons evaluated the relative efficacy of US Food and Drug Administration-approved doses of intravenous rhC1-INH (50 U/kg for patients weighing < 84 kg; 4200 U otherwise) vs oral sebetralstat (600 mg) for the on-demand treatment of HAE attacks. Patient-level data from rhC1-INH trials (C1 1310, C1 1205, and C1 1304 [placebo only]) were reweighted to match aggregate baseline characteristics (i.e., prophylaxis use, pooled attack location) from the sebetralstat KONFIDENT trial; matching variables were identified from a validated, clinician-informed study of treatment effect modifiers. In the primary analysis, time to complete resolution (TTCR) and redosing were compared using unanchored matching-adjusted indirect comparisons. TTCR subgroup analyses were performed for variables not matched for in the primary analysis due to population differences (i.e., attack severity, time to treatment). Scenario and sensitivity analyses were performed to support TTCR results; a scenario analysis was performed to support redosing results. Hazard ratios (HRs) and odds ratios (ORs), with 95% confidence intervals (CIs), were estimated using a weighted Cox proportional hazards model and a weighted logistic regression model, respectively.</p><p><strong>Results: </strong>In the primary analysis, rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84-7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06-0.53) vs sebetralstat. Similar results for TTCR were observed in subgroup analyses of patients with severe/very severe baseline attacks and patients receiving earlier treatment (within the median time to treatment). Scenario and sensitivity analyses confirmed the robustness of these findings.</p><p><strong>Conclusions: </strong>rhC1-INH provides significantly faster symptom resolution and lower redosing rates vs sebetralstat.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Socioeconomic Indicators and Growth Hormone Treatment Patterns for Idiopathic Short Stature in China: A Large-Scale Real-World Study.","authors":"Chunxiu Gong, Xiaoping Luo, Ruimin Chen, Shengquan Cheng, Xinran Cheng, Hongwei Du, Wei Gu, Ke Huang, Xiaoyan Huang, Guimei Li, Ping Li, Tang Li, Li Liang, Deyun Liu, Shu Liu, Yu Liu, Zhe Su, Yan Sun, Chunlin Wang, Naijun Wan, Haiying Wu, Su Wu, Wei Wu, Yu Yang, Hui Yao, Xiaoyong Yuan, Rongxiu Zheng, Min Zhu","doi":"10.1007/s12325-026-03603-6","DOIUrl":"https://doi.org/10.1007/s12325-026-03603-6","url":null,"abstract":"<p><strong>Introduction: </strong>Recombinant human growth hormone (rhGH) treatment for idiopathic short stature (ISS) in China faces challenges including delayed initiation, poor persistence, limited adoption of advanced therapies, and conservative dosing. This study characterized real-world temporal and geographical patterns of rhGH therapy and identified associated socioeconomic factors.</p><p><strong>Methods: </strong>Data from two nationwide registries comprising 24,384 children with ISS initiating rhGH were analyzed. Predictors of treatment effectiveness were identified via linear regression. Provincial variations and temporal trends were assessed via descriptive analysis and seasonal-trend decomposition. Spearman correlation was used to examine associations between treatment patterns and socioeconomic indicators.</p><p><strong>Results: </strong>The median rhGH initiation age was 8.45 years. Most patients (81.3%) initiated short-acting GH (SAGH; median dose 0.15 IU/kg/day), while 18.7% initiated long-acting GH (LAGH; median dose 0.20 mg/kg/week). Younger age and treatment duration ≥ 9 months predicted superior 1-year height standard deviation score gain (P < 0.001). Temporally, LAGH adoption and standard-dose regimens showed significant longitudinal increases (P < 0.05). Geographically, substantial variation existed in median initiation age (7.11-9.70 years), LAGH adoption rates (11.8-31.1%), and duration of therapy (DOT; 10.3-28.1 months). Higher per capita gross regional product correlated with younger initiation (ρ = - 0.530), higher LAGH adoption (ρ = 0.371), and longer DOT (ρ = 0.552). Conversely, higher rural population ratios correlated with delayed initiation, lower LAGH adoption, and shorter DOT (all P < 0.05).</p><p><strong>Conclusion: </strong>Geographic heterogeneity in rhGH therapy is observed and correlates with regional socioeconomic profiles. To enhance therapeutic outcomes and support the balanced development of pediatric endocrine care, adaptive clinical management considering regional socioeconomic contexts is recommended.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes.","authors":"Daniel Bandari, Devon Conway, Liang Dong, Nicholas Hong, Minxing Li, Anne Littlewood, Mike Roy, Sam Ulin, Chencan Zou, Babak Amerian-Williams, Nicholas Belviso, James B Lewin, Jason P Mendoza, Mirla Avila","doi":"10.1007/s12325-026-03608-1","DOIUrl":"https://doi.org/10.1007/s12325-026-03608-1","url":null,"abstract":"<p><strong>Introduction: </strong>Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are established disease-modifying therapies for relapsing multiple sclerosis (RMS). While DRF has demonstrated improved gastrointestinal tolerability compared to DMF, there is limited research evaluating whether this difference in tolerability translates into a difference in clinical effectiveness. This study evaluated the real-world effectiveness of DRF versus DMF on relapse outcomes in persons with MS (pwMS) in a large US population.</p><p><strong>Methods: </strong>This retrospective cohort study utilized the Forian administrative claims database (January 1, 2018-June 30, 2025). Adult pwMS initiating DRF or DMF were identified and propensity score-matched (1:3 ratio) based on baseline demographic and clinical characteristics. Endpoints were assessed over 1- and 2-year follow-up periods. The primary endpoint was annualized relapse rate (ARR).</p><p><strong>Results: </strong>The 1-year analysis included 1780 DRF-treated and 5340 DMF-treated pwMS; the 2-year analysis included 739 DRF-treated and 2217 DMF-treated pwMS. At 1 year of treatment, DRF was associated with a significantly lower ARR compared to DMF (0.12 vs. 0.16; p = 0.03), representing a 21% reduction in relapse rate (rate ratio 0.79; 95% CI 0.64-0.97). At 2 years of treatment, DRF maintained a lower ARR compared to DMF (0.11 vs. 0.16; p = 0.02), reflecting a 31% reduction in relapse rate (rate ratio 0.69; 95% CI 0.54-0.87).</p><p><strong>Conclusion: </strong>The results of this real-world analysis indicate DRF may be more effective than DMF in reducing relapses over 1 and 2 years of treatment in pwMS.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Value and Impact of Weight Reduction from the Perspective of People in Canada with Type 2 Diabetes.","authors":"Melissa M Ross, Sarah Mulnick, Kristina S Boye, Jennifer Glass, Christine Longuet, Ashley Samuelson, Vivian Thuyanh Thieu, Michael Vallis, Meredith M Hoog","doi":"10.1007/s12325-026-03581-9","DOIUrl":"https://doi.org/10.1007/s12325-026-03581-9","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity and overweight are major contributing factors for type 2 diabetes (T2D). Here, we explored the perspectives of people with T2D on the value and expected impacts of reaching a lower weight.</p><p><strong>Methods: </strong>Adult residents of Canada with T2D completed a cross-sectional survey informed by qualitative interviews. Survey questions explored weight management experiences, T2D and weight impacts on quality of life, and the value of losing 5%, 10%, or 20% body weight. Results were summarized descriptively.</p><p><strong>Results: </strong>Of 358 participants, 56% were male and 81% were white, with a mean age of 59 years (SD 13) and a mean self-reported body mass index of 32.9 kg/m² (SD 7.9); 44% of participants had a current hemoglobin A1C < 7%. T2D negatively affected quality of life, particularly impacting emotional well-being (50%), other illnesses (48%), and sleep (49%). Most participants believed their weight affected their T2D (85%), felt they needed to lose weight (89%), struggled to lose weight (79%), and deemed weight management to be crucial for T2D management (94%). Participants' average \"dream\" weight loss was a 19% reduction. Most participants anticipated losing 5%, 10%, or 20% body weight would significantly improve their future with T2D (64%, 75%, or 71%) and overall health (79%, 85%, and 90%), and would have a positive impact (70%, 78%, or 71%), particularly on appearance, comorbidities, and emotional well-being.</p><p><strong>Conclusion: </strong>Participants with T2D valued weight loss and anticipated improvements to their health and quality of life with greater perceived value and impacts associated with increased weight reductions.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.","authors":"Xi Tan, Wan-Lun Tsai, Yuanjie Liang, Caroline Swift, Gang Fang, Chalak Muhammad, Adam de Havenon","doi":"10.1007/s12325-026-03610-7","DOIUrl":"https://doi.org/10.1007/s12325-026-03610-7","url":null,"abstract":"<p><strong>Introduction: </strong>Within the cardiovascular-kidney-metabolic syndrome (CKM) framework, semaglutide has demonstrated benefits beyond glycemic control and weight loss in clinical trials. However, most real-world studies in type 2 diabetes (T2D) have limited assessment of broader cardiometabolic and renal outcomes. We evaluated CKM-relevant outcomes among individuals with T2D who achieved substantial hemoglobin A1c (HbA1c) and weight improvements after initiating semaglutide in real-world settings.</p><p><strong>Methods: </strong>This observational pre-post study used Optum's de-identified Market Clarity Data from January 1, 2007, to June 30, 2024. The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation. We compared baseline (1 year before initiation) with 1st-year and 2nd-year follow-up for cardiometabolic endpoints (3-point and 5-point major adverse cardiovascular events [MACE]), cardiometabolic risk factors, and renal outcomes. Sensitivity analysis was performed in an exploratory cohort of patients in the top tertile of Hb1Ac reduction and weight loss.</p><p><strong>Results: </strong>We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution). Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 years after semaglutide initiation (all p < 0.001). Fewer than 1% of patients experienced a ≥ 40% decline in estimated glomerular filtration rate (eGFR) during follow-up. Mean change in urine albumin-to-creatinine ratio (UACR) were - 20.13 mg/g in the 1st year (p < 0.001) and - 54.03 mg/g in the 2nd year (p < 0.001). The event rate of 3-point MACE decreased from 26.82 per 1000 person-years (PY) during baseline to 22.31 per 1000 PY in the 2nd year. The sensitivity analysis showed consistent results.</p><p><strong>Conclusion: </strong>In this real-world study, semaglutide users who achieved glycemic and weight goals exhibited marked improvements in cardiometabolic and renal outcomes over 2 years.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden of Chronic Rhinosinusitis Without Nasal Polyps: A Systematic Review of Epidemiological, Clinical, Humanistic, and Economic Evidence.","authors":"Anju T Peters, Catherine Rolland, Louis Lavoie, Selwyn Fung, Daniel Basoff, Abhishek Chitnis","doi":"10.1007/s12325-026-03575-7","DOIUrl":"https://doi.org/10.1007/s12325-026-03575-7","url":null,"abstract":"<p><p>Chronic rhinosinusitis (CRS) is a heterogeneous and often debilitating disease characterized by persistent sinonasal symptoms and inflammation and is phenotypically classified as CRS with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP). Although CRSsNP is the more prevalent phenotype (approximately 80%), it remains disproportionately understudied, leading to critical gaps in understanding and management. This systematic literature review synthesized current global evidence on the epidemiological, clinical, humanistic, and economic burden of CRSsNP, highlighting areas of unmet need and raising awareness of the impact of this disease. PRISMA-compliant searches were conducted for CRSsNP records published 2004-2024 (epidemiological studies 2014-2024) across six electronic databases. Targeted hand searches were performed for abstracts (2022-2024), health technology assessments, guidelines, and clinical trial registries. Of 2215 records identified, 157 met inclusion criteria. CRSsNP prevalence was 4.3-10.4% in the USA, South Korea, and Spain. Patients experienced a range of symptoms including nasal/sinus (obstruction, discharge, crusting), pain, sensory (anosmia, cacosmia), respiratory (cough, asthma), oral (dry throat, halitosis), and sleep impairment. There was considerable variability in the availability and use of tools to assess severity; this impeded cross-study comparisons, consistent disease staging, and treatment escalation criteria. Associated comorbidities included asthma, chronic obstructive pulmonary disease, gastroesophageal reflux disease, and primary antibody deficiencies. Humanistic burden was assessed using a variety of outcome measures and was higher for patients with CRSsNP than for controls. Limited data were available on economic burden. Currently available therapies were associated with high rates of treatment failure, inadequately controlled symptoms, and the need for multiple lines of therapy. CRSsNP is associated with considerable burden across clinical, humanistic, and economic domains, exacerbated by diagnostic variability, treatment limitations, and a lack of standardized research methodologies. This highlights the need for coordinated efforts among stakeholders to better address this chronic condition and support future improvements in patient outcomes.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry.","authors":"Anju T Peters, Andréanne Côté, Xavier Muñoz, Changming Xia, Scott Nash, Megan Hardin, Lucía de Prado Gómez, Harry J Sacks, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz","doi":"10.1007/s12325-026-03568-6","DOIUrl":"https://doi.org/10.1007/s12325-026-03568-6","url":null,"abstract":"<p><strong>Introduction: </strong>Coexisting type 2 inflammatory diseases such as allergic rhinitis (AR), atopic dermatitis (AD), chronic rhinosinusitis (CRS) and/or nasal polyposis (NP), eosinophilic esophagitis (EoE), and urticaria are common in asthma. RAPID (NCT04287621), a global prospective registry, aimed to characterize patients with asthma initiating dupilumab in a real-world clinical setting. This analysis investigated the prevalence of coexisting type 2 inflammatory diseases in these patients.</p><p><strong>Methods: </strong>Patients aged ≥ 12 years initiating dupilumab for asthma (primary indication) according to country-specific prescribing information were enrolled in RAPID. Patients had regular assessments at 1 month and thereafter every 3 months for up to 3 years, per standard of care across study sites.</p><p><strong>Results: </strong>At the time of analysis, 205 patients were enrolled. Mean age of patients (stratified by type 2 coexisting disease) ranged from 42.3 to 57.3 years and mean body mass index from 29.9 to 31.8 kg/m². Most patients were female (67.3% to 77.4%), and mean time since asthma diagnosis was 17.3 to 24.0 years, with mean duration of coexisting diseases ranging from 9.8 to 17.0 years. A total of 189 (92%) patients had ≥ 1 ongoing type 2 coexisting disease (AR, 80%; CRS and/or NP, 45% [CRS with NP, 47%; CRS without NP, 41%; NP, 12%]; AD, 27%; urticaria, 15%; and EoE, 3%).</p><p><strong>Conclusion: </strong>This analysis from the RAPID registry shows that type 2 coexisting diseases are highly prevalent in patients with asthma initiating dupilumab in a clinical practice setting and highlights the importance of properly assessing patients to improve patient care.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT04287621.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}